Results 11 to 20 of about 15,809 (234)

Successful Management of <i>Candida auris</i> Bloodstream Infection in an Elderly Patient: A Case Report. [PDF]

Clin Case Rep
ABSTRACT Candida auris is an emerging multidrug‐resistant pathogen frequently misidentified by conventional methods, posing diagnostic and infection‐control challenges, particularly in low‐ and middle‐income countries. We report a 74‐year‐old male in Dhaka, Bangladesh, with multiple comorbidities who developed Candidemia.
Chowdhury AH, Rahman T, Islam N, Sadique T, Khan AR, Sen D, Abdullah A, Mondal D, Ahmed D.   +8 more
europepmc   +2 more sources

A genome-wide screening of potential target genes to enhance the antifungal activity of micafungin in Schizosaccharomyces pombe. [PDF]

PLoS ONE, 2013
Micafungin is a non-reversible inhibitor of 1, 3-β-D-glucan synthase and interferes with fungal cell wall synthesis. Clinically, micafungin has been shown to be efficacious for the treatment of invasive candidiasis and invasive aspergillosis.
Xin Zhou, Yan Ma, Yue Fang, Wugan gerile, Wurentuya Jaiseng, Yuki Yamada, Takayoshi Kuno   +6 more
doaj   +1 more source

Assessment of Micafungin Dosage Regimens in Patients with Cancer Using Pharmacokinetic/Pharmacodynamic Modeling and Monte Carlo Simulation

Antibiotics, 2021
Micafungin is widely used for invasive candidiasis, especially in critically ill patients and those with cancer, and for empirical antifungal therapy in patients with neutropenic fever.
Saeed Alqahtani, Asma Alfarhan, Abdullah Alsultan, Emad Alsarhani, Abdulaziz Alsubaie, Yousif Asiri   +5 more
doaj   +1 more source

Effect of antifungal stewardship on micafungin prescribing practices in intensive care units at a tertiary-care hospital

Antimicrobial Stewardship & Healthcare Epidemiology, 2023
Background: Fungal diseases are associated with substantial global mortality and economic burden, especially in critically ill or immunocompromised patients.
Radhika Arya, Sarah Norman, Farah Daas, Sheena Ramdeen   +3 more
doaj   +1 more source

Characterizing Safety and Clinical Outcomes Associated with High-Dose Micafungin Utilization in Patients with Proven Invasive Candidiasis

Tropical Medicine and Infectious Disease, 2022
Micafungin is the empiric antifungal agent of choice for the treatment of invasive candidiasis (IC). Pathophysiologic changes that occur in obese and/or critically ill patients can alter micafungin serum concentrations and the probability of target ...
Victoria C. Grant, Kenneth Nguyen, Sasha Rodriguez, Anna Y. Zhou, Jacinda C. Abdul-Mutakabbir, Karen K. Tan   +5 more
doaj   +1 more source

Persistent candida arthritis successfully treated with micafungin instillation and surgery. A case report

Medical Mycology Case Reports, 2020
We report a rare case of C. krusei knee arthritis treated with instillation of micafungin and arthroscopy. A 49-year-old man hospitalized for treatment of Acute Myeloid Leukemia developed knee arthritis with C. krusei.
Jeroen C. van Egmond, Nicole G.M. Hunfeld, Bart J.A. Rijnders, Jan A.N. Verhaar   +3 more
doaj   +1 more source

Micafungin for Candida infections in Slovenia and Romania: A multicenter, observational, prospective study

Journal of Infection in Developing Countries, 2021
Introduction: An echinocandin, such as micafungin, is recommended as first-line treatment for invasive Candida infections in immunocompromised patients. This multicenter, observational, prospective, non- interventional study evaluated the real-world use
Samo Zver, Simona Avcin, Ovidiu Bedreag, Sanja Bizilj, Vanja Ecrulj, Janez Jazbec, Nina Puconja, Rade Stanic, Matjaž Jereb   +8 more
doaj   +1 more source

Species Distribution of Candidemia and Their Susceptibility in a Single Japanese University Hospital: Prior Micafungin Use Affects the Appearance of Candida parapsilosis and Elevation of Micafungin MICs in Non-parapsilosis Candida Species

Journal of Fungi, 2021
Introduction: Micafungin is a recommended echinocandin antifungal agent for candidemia treatment and prophylaxis. However, overuse of echinocandin antifungals may cause resistance.
Yasutaka Sakamoto, Kazuhiro Kawabe, Tomoyo Suzuki, Kayoko Sano, Kazuo Ide, Tetsuta Nishigaki, Yuki Enoki, Kazuaki Taguchi, Hirofumi Koike, Hideaki Kato, Yukiko Sahashi, Kazuaki Matsumoto   +11 more
doaj   +1 more source

Plasma and Cerebrospinal Fluid Concentrations of Micafungin Administered at High Doses in Critically Ill Infants with Systemic Candidiasis: A Pooled Analysis of Two Studies

Pharmaceuticals, 2023
Background: Neonates may require higher doses of micafungin than adults to reach the therapeutic effect for increased plasma clearance. Only poor and inconclusive data are available still now to support this hypothesis, especially with regard to central ...
Domenico Umberto De Rose, Iliana Bersani, Maria Paola Ronchetti, Fiammetta Piersigilli, Sara Cairoli, Andrea Dotta, Amit Desai, Laura Lynn Kovanda, Bianca Maria Goffredo, Cinzia Auriti   +9 more
doaj   +1 more source

First Report of Fluconazole-Resistant Candida parapsilosis Harbouring the G458S ERG11p Substitution in a Brazilian Hospital. [PDF]

Mycoses
ABSTRACT Background Fluconazole‐resistant Candida parapsilosis is a matter of concern. Objectives To investigate fluconazole resistance among Candida parapsilosis complex isolates from patients admitted to three Brazilian hospitals, and to characterise resistance mechanisms and clonal relatedness. Patients/Methods A total of 76 C.
Gonçalves SS, Maifrede SB, Yäkel E, Peçanha PM, Bessa-Neto FO, Cayô R, Rodrigues AM, Muñoz P, Escribano P, Guinea J.   +9 more
europepmc   +2 more sources